title: Ocular fundus changes in malignant or precocious stroke-prone spontaneously hypertensive rats after administration of antihypertensive drugs.
abstract: 1. Malignant or precocious stroke-prone spontaneously hypertensive rats (M-SHRSP) showed hypertensive ocular fundus changes with severe hypertension, but various anti-hypertensive drugs given over a proper period improved funduscopic findings. 2. We treated a M-SHRSP with SQ29,852 (an angiotensin converting enzyme inhibitor, ACEI) or manidipine (a calcium antagonist) and observed hypertensive vascular changes in the fundus. 3. The M-SHRSP treated with anti-hypertensive drugs lived longer and the hypertensive fundic changes improved in both groups. But there were some differences of histochemical staining reaction on the endothelial cell-surface and mucopolysaccharides accumulations between the treated group of ACEI and the group treated with the calcium antagonist. 4. In the treated group with calcium antagonist, the anionic ion functions of the endothelial cell-surface were impaired and organic retinal or choroidal damages appeared to have deteriorated.
authors.affiliation: Department of Ophthalmology, Osaka-fu Saiseikai Tondabayashi Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hamada
authors.forename: E
authors.initials: E
authors.lastname: Niisato
authors.forename: T
authors.initials: T
authors.lastname: Otori
authors.forename: T A
authors.initials: TA
authors.lastname: Chikugo
authors.forename: Y
authors.initials: Y
authors.lastname: Ohta
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Okamoto
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001160:Arterioles / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000235:genetics / Q000503:physiopathology; D004095:Dihydropyridines / Q000627:therapeutic use; D005654:Fundus Oculi; D006651:Histocytochemistry; D006973:Hypertension / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009578:Nitrobenzenes; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010879:Piperazines; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009578:Nitrobenzenes; D009943:Organophosphorus Compounds; D010879:Piperazines; C054218:manidipine; D011392:Proline; C054518:ceronapril